US vaping imports: what entry data and product records can—and cannot—establish
Also in Market Access
Summary: For ENDS importers, a submission tracking number, establishment registration and an ACE response answer different questions. The useful evidence chain connects the exact product and business activities to marketing status, entry data and FDA import review—without treating any one record as nationwide permission to sell.
Scope and verification date: US federal requirements and selected official import materials examined on 19 November 2026 (Asia/Shanghai) for manufacturers, importers and supply-chain compliance readers dealing with non-therapeutic consumer electronic nicotine delivery systems (ENDS). This is not a shipment assessment, a customs-filing manual or a survey of destination laws. The United States Code edition examined runs through 10 November 2026; the eCFR pages display Title 21 as up to date through 17 November 2026. Those text cutoffs are not new commencement dates.
Start with the claim, not the number
“We have an STN” is not the same claim as “FDA has authorized this product.” Nor does a supplier’s establishment registration answer whether a particular import entry is admissible. Before relying on a document, identify the question it can actually answer.
| Record or status | Question it helps answer | What it does not establish by itself |
|---|---|---|
| Product-specific marketing record | What FDA decision or other applicable statutory basis concerns this product? | Compliance with every import or destination requirement |
| Establishment registration and product listing | What establishment, activities and products have been registered or listed under the applicable provisions? | A product marketing authorization |
| STN and ACE entry data | Which submission and declared entry information are being identified? | A favorable marketing decision or guaranteed admission |
| FDA entry response | What action or status concerns this entry or line? | A nationwide sales licence or a substitute for the product’s marketing records |
The distinctions follow from the separate marketing, registration and import provisions; they are a way to evaluate evidence, not an additional approval route. Section 910, section 905 and FDA’s ACE explanation address different regulatory questions.
First establish the product’s marketing basis—and the importer’s actual role
Section 910 of the FD&C Act, 21 U.S.C. §387j, defines a “new tobacco product” by reference to 15 February 2007 and later modifications. It generally requires a marketing order, while specifying substantial-equivalence and exemption routes and particular transitional provisions. It does not make an import declaration a route around premarket review, or put every tobacco product into an identical PMTA process.
For a PMTA-based marketing claim, the relevant evidence is the actual marketing-granted order and the product it covers—not merely an application number. 21 CFR §1114.3 defines an STN as a number FDA assigns to submissions it receives, such as a PMTA or supplemental PMTA. The same section separately defines a marketing-granted order as an order stating that the new tobacco product may be introduced or delivered for introduction into interstate commerce. A submission identifier and a favorable decision are therefore different records. Matching the product described in the order to the product being shipped is a substantive evidence question, not a number-format check.
Registration requires a different analysis. FDA’s Importing and Exporting page says importers of finished tobacco products may be distributors, manufacturers or both. It also says importers that do not own or operate a domestic establishment engaged in manufacture, preparation, compounding or processing are not required to register that establishment or provide product listing, but must meet other applicable tobacco-product manufacturer requirements.
That is a conditional statement about domestic activities—not an exemption from FDA regulation for anyone calling itself an importer. Section 905 connects domestic establishment registration to actual operations; its definition includes repackaging or changing package labelling in furtherance of distribution. Ask who performs those activities and where. Do not infer the answer solely from a company’s invoice description, foreign address or status as importer of record. This report does not determine the registration position of a foreign manufacturing establishment.
What the entry data rules and the March 2026 guide actually say
CBP operates ACE, while FDA reviews matters within its import jurisdiction. The definition of an ACE filer concerns the person authorized to submit an electronic import entry; that filing role should not be confused with the product’s manufacturer or the activities of a domestic establishment.
For the tobacco entries addressed here, 21 CFR §1.72 requires the FDA country of production, complete FDA product code consistent with the invoice description, full intended-use code, and importer-of-record telephone and email details. Section 1.79(a) adds the brand name—or a commercial name if there is no specific brand. Its exception is precise: this data element does not apply to products solely intended for further manufacturing or as investigational tobacco products. It is not a general exemption from entry requirements.
The technical source examined is the FDA Supplemental Guide, Version 2.6, dated 10 March 2026, available from CBP’s guidance page. Its tobacco section distinguishes consumer-use, further-manufacturing and investigational processing. It also distinguishes mandatory, conditional and optional records; treating every item as simply “required” loses important information. Its mandatory entity-role table separately identifies the manufacturer, shipper, FDA importer (importer of record) and delivered-to party (printed page 236, Table 12-11). These are not interchangeable names for the filer.
One detail matters particularly for ENDS:
- On printed page 240, section 12.10 labels the PG23 affirmation-of-compliance record “Optional.”
- On printed page 241, Table 12-18, itself labelled optional, says TST—the Tobacco Submission Tracking Number—“should be entered” when the processing code is CSU (consumer use) and the product-code class is L or M. The table also says PID should be entered where CSU applies and TST is provided.
Both parts belong in the account. The guide’s optional record label is not a sensible basis for telling every ENDS importer to omit TST; its conditional “should” language is not, by itself, evidence that a proposed regulation became a binding final rule. These are technical instructions in the particular guide version, not a product authorization or a complete transaction-specific determination of filing obligations. This article does not supply a full message set or filing-code tutorial.
The 2024 STN proposal must be read as a dated rulemaking document
The notice published on 16 August 2024, 89 FR 66647–66655, FR Doc. 2024-18343, was a proposed rule, identified by RIN 0910-AI64 and docket FDA-2024-N-1111. It proposed requiring an STN at entry for ENDS products through ACE or another CBP-authorized electronic system. It did not propose the same requirement for every category of tobacco product.
The proposal’s statement that STN submission was “currently” optional describes the position stated in that 2024 document; it is not a certification of every present-day filing scenario. The comment deadline was 15 October 2024. Section VI proposed effectiveness 30 days after publication of a final rule—not 30 days after the proposal, and not an independently fixed implementation date.
The §1.79 text displayed through 17 November 2026 has the brand-name provision in paragraph (a) and “[Reserved]” in paragraph (b). That is the codified text examined, separately from the March 2026 technical guide. Verification for this report does not establish an exhaustive post-proposal rulemaking history. It neither declares that no later final instrument exists nor turns the 2024 proposal into an operative obligation. Before relying on a claimed change, the evidence needed is the actual later instrument, its scope and effective or implementation dates—not the proposal’s title, an agenda target or a search result alone.
The practical point is narrower and useful: keep the product’s submission records available, identify the guide version and processing category being used, and distinguish a technical data instruction from a claimed change in binding law. No universal “STN never needed” or “STN guarantees entry” conclusion follows from these materials.
Data acceptance, FDA review and “May Proceed” are different stages
FDA’s ACE FAQ explains that CBP transmits relevant entry information to FDA, which performs its review under FDA-administered law. It also distinguishes rejection for missing complete and accurate data from an FDA admissibility review. A system’s acceptance of data is not the same evidence as FDA’s response to the entry line.
FDA’s entry-screening explanation, dated 9 October 2024, describes electronic screening and possible requests for information, examination or sampling where entries are flagged. Complete data can help the process; it does not determine the marketing status of the underlying product.
The explanation accompanying the 2024 STN proposal is explicit about another commonly overstated message: an automated “May Proceed” does not constitute FDA’s determination of the article’s compliance status and does not preclude later FDA action. Its discussion of faster automated review concerned matching entry information to FDA’s data, not creating marketing authorization through a successful data match.
Admissibility has its own legal basis. Section 801(a), 21 U.S.C. §381(a), provides for refusal where a product appears, among other specified grounds, adulterated or misbranded, subject to the statutory provisions. A well-formed entry cannot resolve an adverse product-status issue merely because the data were accepted. Equally, a product marketing record is not a promise about the handling or outcome of a particular shipment.
Read the actual import alert, including its scope and qualifications
FDA’s Import Alert 98-07 addresses ENDS lacking required premarket authorization, including components and parts within its stated scope. The page examined displays 18 September 2026 as its published date and describes a 4 September 2026 revision to its reason and guidance sections. Those are different dates, neither of them the access date.
Its guidance says divisions may detain unauthorized ENDS without physical examination under the stated enforcement-priority approach. It also calls for Center concurrence “as necessary” before detention or refusal to determine whether a product falls within the May 2026 guidance or whether another reason, such as a court order, means it should not be detained or refused. That qualification is material; the alert is not a prediction of the result for every product or entry.
The May 2026 enforcement guidance is nonbinding. It expressly gives no guarantee against case-by-case enforcement and says falling within its policy has no bearing on the likelihood of eventual premarket authorization. An STN or a pending application alone does not establish that a product satisfies the policy’s conditions. This report does not assess an individual product’s eligibility or the effect of a particular court order.
Import Alert 98-06 is different: its stated scope is new tobacco products other than ENDS, and its guidance concerns products identified on its Red List. Its page displays 22 October 2026 as the published date and likewise describes a 4 September 2026 revision. Do not transplant that alert’s list-based wording into a conclusion that only named ENDS can be detained under 98-07. Conversely, not finding a name on a list is not affirmative evidence of marketing authorization. Both alerts identify themselves as guidance to FDA field personnel, not instruments creating rights or binding FDA or the public.
The destination question remains separate
A federal entry record cannot answer every question about sale or distribution at the destination. 21 U.S.C. §387p preserves specified additional or more stringent measures, including certain sale and distribution restrictions, while also preempting specified State and local requirements and providing exceptions to that preemption. It separately preserves State, tribal and local tobacco taxation.
That structure matters more than the slogan “federal clearance.” It does not establish that any selected State, locality or tribe allows a product or sales channel, or that their powers are identical. This article has not assessed destination licences, restrictions, taxes or remote-sales obligations.
For a commercial decision, request distinct evidence for distinct claims:
- Product: the exact identity and actual marketing record or other applicable statutory basis, rather than an STN alone.
- Business: the responsible parties, the activities they perform and the location of any relevant establishment, rather than a single importer/manufacturer label.
- Entry: the declared product and intended use, the applicable data instructions, and the actual FDA entry-line response—not merely proof of electronic submission.
- Destination: the separately applicable rules for the proposed destination and channel, which this federal account does not determine.
These questions help expose missing or mismatched evidence. They are not a checklist that makes a shipment admissible or a product lawful nationwide.
For the related distinction between PMTA progress, enforcement policy and dated court developments, see VapeVisa’s US PMTA and enforcement-policy report, published 19 November 2026. It provides reporting context, not product-specific clearance.
Official sources and document dates
All sources below were examined on 19 November 2026 (Asia/Shanghai). Statutory edition and eCFR display cutoffs are stated above; guide and webpage dates describe those sources, not a guarantee that no later action exists.
- 21 U.S.C. §387j, section 910: new products, premarket review and specified alternatives.
- 21 U.S.C. §387e, section 905: actual establishment activities, registration and listing.
- FDA ACE frequently asked questions, printed pages 1 and 3, questions 1 and 6. Publication date not displayed in the document examined; used for process distinctions, not as the current field-by-field specification.
- 21 CFR §1114.3: STN, marketing-granted-order and manufacturer definitions.
- FDA, Importing and Exporting, content dated 3 January 2025; used for the conditional domestic-importer explanation, not proof of the absence of later STN rulemaking.
- 21 CFR §1.71: ACE-filer and ACE definitions.
- 21 CFR §1.72: general data elements for the covered FDA-regulated entries.
- 21 CFR §1.79: tobacco brand-name data and its stated exception; paragraph (b) displayed as reserved.
- FDA Supplemental Guide, Version 2.6, 10 March 2026, tobacco section 12; particularly printed pages 228, 236 and 240–241.
- CBP, FDA Supplemental Guide landing page, modified 12 March 2026; links the dated Version 2.6 attachment.
- 89 FR 66647–66655, FR Doc. 2024-18343, published 16 August 2024; proposed rule, especially sections I, V and VI and proposed §1.79(b).
- FDA, Entry Screening Systems and Tools, content dated 9 October 2024.
- 21 U.S.C. §381(a), section 801: import examination and refusal provisions.
- FDA Import Alert 98-07, displayed published date 18 September 2026; described revision 4 September 2026. Selected scope and guidance, not a shipment assessment.
- Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization, cover dated May 2026, especially printed pages 2–5; nonbinding guidance.
- FDA Import Alert 98-06, displayed published date 22 October 2026; described revision 4 September 2026. Scope and guidance distinguished from 98-07; no complete Red List assessment.
- 21 U.S.C. §387p, section 916: preservation, preemption, exceptions and taxation boundaries.
Information for business research, not legal advice or a product or shipment guarantee. No continuing monitoring is promised.